Outcome variable | Independent variables | Regression coefficient (β) (95% CI) | P value |
SDAI | Age | 0.011 (−0.029 to 0.050) | 0.591 |
RA duration | 0.092 (0.049 to 0.135) | <0.001 | |
Baseline SDAI | 0.591 (0.535 to 0.646) | <0.001 | |
Biologic use | 0.463 (−0.862 to 1.787) | 0.493 | |
Early menopause | 1.212 (0.250 to 2.175) | 0.014 | |
Follow-up time | −1.850 (−2.033 to −1.667) | <0.001 | |
CDAI | Age | 0.012 (−0.025 to 0.049) | 0.531 |
RA duration | 0.096 (0.056 to 0.137) | <0.001 | |
Baseline CDAI | 0.577 (0.522 to 0.632) | <0.001 | |
Biologic use | 0.778 (−0.597 to 2.152) | 0.267 | |
Early menopause | 1.105 (0.229 to 1.980) | 0.013 | |
Follow-up time | −1.756 (−1.925 to −1.587) | <0.001 | |
DAS28 | Age | 0.003 (−0.003 to 0.010) | 0.335 |
RA duration | 0.016 (0.009 to 0.023) | <0.001 | |
Baseline DAS28 | 0.617 (0.561 to 0.672) | <0.001 | |
Biologic use | 0.236 (0.020 to 0.452) | 0.032 | |
Early menopause | 0.211 (0.053 to 0.369) | 0.009 | |
Follow-up time | −0.311 (−0.339 to −0.283) | <0.001 | |
HAQ-DI | Age | 0.007 (0.004 to 0.010) | <0.001 |
RA duration | 0.011 (0.008 to 0.014) | <0.001 | |
Baseline HAQ-DI | 0.682 (0.643 to 0.721) | <0.001 | |
Biologic use | 0.040 (−0.054 to 0.134) | 0.400 | |
Early menopause | 0.099 (0.027 to 0.171) | 0.007 | |
Follow-up time | 0.000 (−0.014 to 0.014) | 0.968 | |
EQ-5D utility values | Age | −0.002 (−0.003 to −0.000) | 0.008 |
RA duration | −0.004 (−0.005 to −0.002) | <0.001 | |
Baseline EQ-5D utility value | 0.537 (0.491 to 0.584) | <0.001 | |
Biologic use | −0.016 (−0.054 to 0.022) | 0.405 | |
Early menopause | −0.031 (−0.061 to −0.001) | 0.040 | |
Follow-up time | 0.010 (0.005 to 0.016) | <0.001 |
All covariates adjusted in the model were listed as independent variables.
CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score using 28 joint counts; EQ-5D, EuroQol-5D; HAQ-DI, Health Assessment Questionnaire–Disability Index; SDAI, Simplified Disease Activity Index.